A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
Clinical trial NCT03303313 · WITHDRAWN
Trial details
- NCT number
- NCT03303313
- Sponsor
- Alnylam Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-19
- Primary completion
- 2018-09-12
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.